RareSearch logo

Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

50+ personnel
Headquartered in Chandler
Established in 2026
Website
Dwayne Hermiston profile

Dwayne Hermiston

🇸🇦 Saudi Arabia

9.1

    Reviewed:

  • - HTA Submission
  • - 8 weeks February - March 2024
  • - Biotech Company

Comprehensive and well-executed HTA submission.

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Seth Bashirian profile

Seth Bashirian

🇧🇷 Brazil

9.5

    Reviewed:

  • - Gene Therapy Development
  • - 12 weeks January - March 2023
  • - Research Institution

Innovative approach to gene therapy development, collaborative team.

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Simon Rau profile

Simon Rau

🇸🇦 Saudi Arabia

8.8

    Reviewed:

  • - Companion Diagnostics Development
  • - 16 weeks January - May 2024
  • - Pharmaceutical Company

High-quality companion diagnostics development, delivered on time.

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Luis Homenick profile

Luis Homenick

🇲🇽 Mexico

5.7

    Reviewed:

  • - Project Management
  • - 12 weeks March - May 2024
  • - Biotech Company

Poor communication and missed deadlines caused frustration.

Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.

Mr. Ruben Murray profile

Mr. Ruben Murray

🇮🇹 Italy

8.9

    Reviewed:

  • - Stability Studies
  • - 18 months January 2023 - June 2024
  • - Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Jeremy Abbott profile

Jeremy Abbott

🇮🇹 Italy

8.7

    Reviewed:

  • - Patient Recruitment
  • - 8 weeks March - April 2023
  • - Clinical Research Organization

Highly effective patient recruitment strategies, project completed on time.

The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.

Geneva Mann profile

Geneva Mann

🇦🇺 Australia

8.9

    Reviewed:

  • - Regulatory Submission
  • - 6 weeks February 2023
  • - Biotech Startup

Professional and knowledgeable, seamless regulatory submission process.

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.

Doug McClure profile

Doug McClure

🇬🇧 United Kingdom

9

    Reviewed:

  • - Process Development
  • - 12 weeks March - May 2024
  • - Biotech Company

Expert process development, enhanced efficiency.

The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.

Ms. Lynn Kassulke profile

Ms. Lynn Kassulke

🇮🇳 India

6

    Reviewed:

  • - Health Technology Assessment
  • - 8 weeks July - September 2024
  • - Pharmaceutical Company

Health technology assessment was superficial, lacked thorough analysis.

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.